Compare NIU & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | RLMD |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.6M | 319.0M |
| IPO Year | 2018 | N/A |
| Metric | NIU | RLMD |
|---|---|---|
| Price | $3.24 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 721.5K | ★ 1.0M |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $625,182,280.00 | N/A |
| Revenue This Year | $42.51 | N/A |
| Revenue Next Year | $23.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.99 | N/A |
| 52 Week Low | $1.66 | $0.24 |
| 52 Week High | $5.67 | $5.12 |
| Indicator | NIU | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 58.07 |
| Support Level | $2.89 | $4.28 |
| Resistance Level | $3.40 | $4.75 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 64.36 | 58.02 |
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.